Hims & Hers Health Inc Stock Price, News & Analysis

Hims & Hers Health (NYSE: HIMS) has released compelling data demonstrating the success of its personalized weight loss program featuring GLP-1 treatments. The analysis revealed that customers lost an average of 20.9 pounds (10.3% of initial body weight) within six months, with a remarkable 75% retention rate during the treatment period.

The company's holistic approach combines personalized GLP-1 dosing with 24/7 care team access and comprehensive wellness support. Key metrics include a low 10.3% side effect rate, with only 4.5% reporting intolerable effects. The platform facilitated over 6.7 million customer-care team messages, with 75% of responses delivered within 5 hours. Notably, 97% of customers reported improved overall health, and 73% preferred Hims & Hers' digital health experience over alternatives.

Hims & Hers Health (NYSE: HIMS), the leading health and wellness platform, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results.

Additionally, management will participate in the Canaccord Genuity's 45th Annual Growth Conference on August 13, 2025 in Boston.

Hims & Hers Health (NYSE: HIMS) has announced plans to expand into Canada in 2026, coinciding with the first-ever availability of generic semaglutide globally. This strategic expansion follows the company's recent acquisition of European digital health platform ZAVA.

The expansion aims to address a significant market need, as nearly two-thirds of Canadian adults are overweight or living with obesity. The company plans to offer affordable weight loss treatment through its digital platform, featuring 24/7 access to licensed providers and personalized care plans. Currently, branded semaglutide in Canada costs over C$200 monthly, but generic versions are expected to be available at a significant discount.

Hims & Hers Health (NYSE: HIMS) has announced plans to acquire ZAVA, a leading European digital health platform, marking a significant expansion into European markets including the UK, Germany, France, and Ireland. ZAVA currently serves over 1.3 million active customers and completed nearly 2.3 million consultations in 2024. The acquisition, expected to close in H2 2025, will be funded entirely in cash from Hims & Hers' balance sheet. The company plans to establish its branded presence across these markets, offering personalized healthcare services in local languages across dermatology, weight loss, sexual health, and mental health. The deal is expected to be accretive by 2026, with ZAVA's established infrastructure and medical expertise complementing Hims & Hers' proven brand and healthcare platform.

Hims & Hers Health (NYSE: HIMS) has launched a new pricing initiative for Wegovy®, offering eligible new customers access to the prescription-only weight loss treatment at $549 per month for 6 months through a limited-time offer. The program includes access to the company's comprehensive weight loss approach, featuring technology-driven solutions and holistic care options.

CEO Andrew Dudum emphasized the company's commitment to increasing healthcare accessibility. The platform continues to provide various weight loss solutions, including medications, oral kits, protein supplements, nutrition kits, and clinically-backed care plans, tailored to customers' needs, goals, and eligibility.

Hims & Hers Health (NYSE: HIMS) has priced an upsized $870 million convertible senior notes offering due 2030, with an additional $130 million option for initial purchasers. The zero-interest notes have an initial conversion price of $70.67 per share, representing a 37.5% premium over the last closing price of $51.40.

The company expects net proceeds of approximately $842.7 million (potentially $968.8 million if the additional option is exercised). The funds will be used to accelerate global expansion through organic growth and strategic acquisitions, enhance AI capabilities, develop diagnostic tools, and advance personalized treatments. About $41.6 million will fund capped call transactions to reduce potential dilution.

Hims & Hers Health (NYSE: HIMS) has announced plans to offer $450 million in convertible senior notes due 2030, with an additional option for purchasers to buy up to $67.5 million. The notes will be offered privately to qualified institutional buyers under Rule 144A. The proceeds will fund the company's global expansion initiatives, both through organic growth and potential strategic acquisitions, though no definitive agreements are currently in place. Additionally, the funds will support enhanced AI development, data pipeline expansion, and advancement of personalized treatments under new CTO Mo Elshenawy. The notes will be senior, unsecured obligations with semi-annual interest payments, convertible under certain conditions into cash, Class A common stock, or a combination thereof. The company plans to enter into capped call transactions to reduce potential dilution and offset potential cash payments above the principal amount.

Hims & Hers Health (NYSE: HIMS) has appointed Mo Elshenawy as its new Chief Technology Officer, marking a significant step in the company's AI-driven healthcare vision. Elshenawy, former President and CTO at Cruise, brings over 20 years of technology sector experience, including expertise in AI, product development, and engineering.

At Cruise, he led the launch of the first commercial driverless rideshare service in San Francisco. His previous experience includes senior leadership roles at Amazon, where he managed global engineering for ReCommerce and developed retail data analytics platforms. Elshenawy holds more than 10 patents in AI, robotics, and autonomous vehicles.

The appointment aligns with Hims & Hers' strategy to build a next-generation healthcare platform powered by AI, focusing on personalized care delivery at scale. The company plans to expand its MedMatch system and invest in AI to enhance diagnosis and improve health and wellness experiences.

Hims & Hers Health (NYSE: HIMS) reported exceptional Q1 2025 financial results, with revenue surging 111% year-over-year to $586.0 million. The company achieved net income of $49.5 million and Adjusted EBITDA of $91.1 million. Subscriber base grew 38% YoY to 2.4 million, with monthly online revenue per average subscriber increasing 53% to $84.

The company maintained its 2025 revenue guidance of $2.3-2.4 billion and raised Adjusted EBITDA guidance to $295-335 million. Notably, Hims & Hers introduced ambitious 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA. For Q2 2025, the company expects revenue of $530-550 million and Adjusted EBITDA of $65-75 million.